No Abstract BioWorld International CorrespondentIntercell AG entered a marketing and distribution agreement with Novartis AG under which the latter company will sell its Japanese encephalitis virus (JEV) vaccine, IC51, in the U.S., Europe, Japan, Latin America and other selected territories.